Buclizine Hydrochloride, Paracetamol, Codeine Phosphate — Drug Intelligence | 46 EU Trials

Filter these 46 trials by condition, phase, country and more.

Open in Search →

46 Registered trials

21 Recruiting

22 Completed trials

20 Sponsors

21 Countries

Phase III

Phase II

Phase I/II

Phase I (FiH)

Phase III: 18 Phase II: 13 Phase I/II: 8 Phase I: 1 Phase I (FiH): 6

Oversight events:

4 serious breaches 14 temporary halts 2 urgent safety measures 6 unexpected events 5 corrective measures across 15 trials

View oversight register →

Indications tested

Plasma cell myeloma 2 B-cell lymphoma refractory 2 Non-small cell lung cancer 2 Ewing's sarcoma 1 IgA nephropathy 1 Neuroblastoma 1 Non-small cell lung cancer stage IIIB 1 Acute myeloid leukaemia refractory 1 Blastic plasmacytoid dendritic cell neoplasia 1 End stage renal disease 1 Hormone receptor positive breast cancer 1 Myelodysplastic syndrome 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 17 Genmab A/S 4 Sanofi-Aventis Recherche & Developpement 4 Apurano Pharmaceuticals GmbH 3 Cannaxan GmbH 3 Moderna Inc. 3 Amgen Inc. 2 Biogen Idec Research Limited 1 Centre Hospitalier Universitaire De Nantes 1 Centre Oscar Lambret 1 F. Hoffmann-La Roche AG 1 Medical University Of Vienna 1

All trials — page 2

46 total

Study of SKB264 to treat participants with advanced non-small cell lung cancer alone or as a combination treatment Ended

2023-507270-41-00 Phase II 2 countries Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.
Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph… Ended

2023-505989-29-00 Phase III 16 countries Amgen Inc.
A Phase 1/2 Study of MK-2870 plus EV plus Pembrolizumab in la/mUC Ended

2023-506387-14-00 Phase I (FiH) 5 countries Merck Sharp & Dohme LLC
A research study to look at long-term treatment with a medicine called NNC6019-0001 for people who have heart failure due to transthyretin a… Ended

2022-502605-15-00 Phase II 7 countries Novo Nordisk A/S
A clinical study of MK-2870 in people with stomach cancer (MK-2870-015) Ended

2023-505423-31-00 Phase III 7 countries Merck Sharp & Dohme LLC
Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone… Ended

2023-508310-41-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes
International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximab Ended

2023-507180-19-00 Phase II 7 countries Sanofi-Aventis Recherche & Developpement
EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Ended

2023-504832-16-00 Phase II 8 countries Genmab A/S
A study to investigate subcutaneous isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or … Ended

2023-508870-27-00 Phase II 3 countries Sanofi-Aventis Recherche & Developpement
A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended

2023-504830-23-00 Phase III 13 countries Genmab A/S
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended

2023-504805-35-00 Phase I/II 10 countries Genmab A/S
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with ISN/RPS 2003 Class III or IV Lupus Nephritis Ended

2023-503628-22-00 Phase III 5 countries F. Hoffmann-La Roche AG
Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma Ended

2023-507419-37-00 Phase III 11 countries Sanofi-Aventis Recherche & Developpement
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended

2023-504802-12-00 Phase I (FiH) 9 countries Genmab A/S
A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokine… Ended

2022-502963-39-00 Phase I (FiH) 4 countries Moderna Therapeutics Inc.
Efficacy and Tolerability of AP707 in Patients with chronic Pain due to traumatic or post-operative peripheral Neuropathy Ended

2022-500898-13-00 Phase III 2 countries Apurano Pharmaceuticals GmbH; Cannaxan GmbH
Efficacy and Tolerability of AP707 in Patients with chronic pain due to central Neuropathy of any Genesis Ended

2022-500899-66-00 Phase III 2 countries Apurano Pharmaceuticals GmbH; Cannaxan GmbH
Efficacy and Tolerability of AP707 in Patients with Chronic Back Pain Ended

2022-502151-54-00 Phase III 2 countries Apurano Pharmaceuticals GmbH; Cannaxan GmbH
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) Ended

2023-508422-95-00 Phase I/II 1 country Synthorx Inc.
First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leuk… Ended

2023-508357-58-00 Phase I (FiH) 2 countries Sanofi-Aventis Recherche & Developpement
Study to evaluate the efficacy and safety of a local anesthetic used in flat foot or inguinal hernia interventions at two different concentr… Ended

2024-518179-76-00 Phase II 1 country Sintetica S.A.
A dose-finding study to evaluate mRNA-3210 in participants with phenylketonuria Ended

2023-506963-32-00 Phase I (FiH) 3 countries Moderna Therapeutics Inc.

Showing 25–46 of 46 trials

← All drugs A–Z